TP53 and acute myeloid leukemia: Unplanned subgroup analyses and post hoc evaluations have demonstrated that the rate of complete remission (CR)/CR with incomplete count recovery (CRi) for patients with TP53m-AML after cytarabine–anthracycline therapy, either classical “7 + 3” or the liposomal formulation CPX-351, is 20–40% [8,21,23,32,33]; this is in contrast to the 80% rate of CR that is observed for patients with the TP53 wild-type disease (Table 1) [21,23,24,32].